



**HAL**  
open science

# Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate or High-Risk Acute Myeloid Leukemia in Complete Remission: a Study From the ALWP of the EBMT

Florent Malard, Myriam Labopin, Gernot Stuhler, Jörg Bittenbring, Arnold Ganser, Johanna Tischer, Mauricette Michallet, Nicolaus Kröger, Christoph Schmid, Anne Huynh, et al.

## ► To cite this version:

Florent Malard, Myriam Labopin, Gernot Stuhler, Jörg Bittenbring, Arnold Ganser, et al.. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate or High-Risk Acute Myeloid Leukemia in Complete Remission: a Study From the ALWP of the EBMT. *Biology of Blood and Marrow Transplantation*, 2016, 10.1016/j.bbmt.2016.11.002 . hal-01393932

**HAL Id: hal-01393932**

**<https://hal.sorbonne-universite.fr/hal-01393932>**

Submitted on 8 Nov 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

FLAMSA RIC for AML in CR

1 **Sequential intensified conditioning regimen allogeneic hematopoietic stem**  
2 **cell transplantation in adult patients with intermediate or high-risk acute**  
3 **myeloid leukemia in complete remission: a study from the ALWP of the**  
4 **EBMT**

5 Florent Malard<sup>1,2,3</sup> MD, PhD, Myriam Labopin<sup>1</sup> MD, Gernot Stuhler<sup>4</sup> MD, Jörg  
6 Bittenbring<sup>5</sup> MD, Arnold Ganser<sup>6</sup> MD, Johanna Tischer<sup>7</sup> MD, Mauricette Michallet<sup>8</sup>  
7 MD, PhD, Nicolaus Kröger<sup>9</sup> MD, Christoph Schmid<sup>10</sup> MD, Anne Huynh<sup>11</sup> MD,  
8 Michael Hallek<sup>12</sup> MD, Bipin N Savani<sup>13</sup> MD, Mohamad Mohty<sup>1,2,3,14</sup> MD, PhD, Arnon  
9 Nagler<sup>14,15</sup> MD, MSc

10 1- Department of Haematology, Saint Antoine Hospital, Paris, France

11 2- INSERM UMRs 938, Paris, France

12 3- Pierre et Marie Curie University, Paris, France;

13 4- German diagnostic clinic, ZMT Center, Wiesbaden, Germany

14 5- University of Saarland, University Hospital, Dept. of Internal Med. BMT Unit,  
15 Homburg, Germany

16 6- Hannover Medical School, Department of Haematology, Hemostasis, Oncology  
17 and Stem Cell Transplantation, Hannover, Germany

18 7- Ludwig-Maximilians-University Hospital of Munich-Campus Grosshadern,  
19 Department of Internal Medicine III, BMT unit, Munich, Germany

20 8- University Hospital Lyon Sud, Department of Haematology, Lyon, France

21 9- University Hospital Eppendorf, Bone Marrow Transplantation Centre,  
22 Hamburg, Germany

23 10- Augsburg Hospital, Department of Internal Medicine, Augsburg, Germany

24 11- IUCT Oncopole, Hematology Department, Toulouse, France

25 12- University of Cologne, Dept of Medecine, Cologne, Germany

FLAMSA RIC for AML in CR

26 13- Vanderbilt University, Haematology and Transplantation, Nashville, USA

27 14- EBMT Paris Study Office/CEREST-TC, Paris, France

28 15- Hematology division, Chaim Sheba medical Center, Tel-Hashomer, Israel

29 **Running title:** FLAMSA RIC for AML in CR

30 **Word count:** abstract: 229 words; main text: 2880; pages: 23; tables: 3; figure: 1.

31 **Author for correspondence:**

32 Florent Malard, M.D., Ph.D.; Service d'Hématologie Clinique et de Thérapie

33 Cellulaire, Hôpital Saint Antoine, APHP, Université Pierre et Marie Curie and

34 INSERM, UMRs 938, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.

35 Phone : +33 149282629 ; Fax : +33 149283375

36 Email : [malardf@yahoo.fr](mailto:malardf@yahoo.fr)

37

38 **Highlights**

39 • FLAMSA provides an efficient disease control in intermediate and high-  
40 risk AML.

41 • Leukemia-free survival at 2 years was 52.8% (95%CI, 46.4-59.2).

42 • Overall-free survival at 2 years was 56.1% (95%CI, 49.7-62.6).

43

44 **Abstract**

45 Post-transplant relapse is the leading cause of treatment failure in acute myeloid

46 leukemia (AML) patients after reduced intensity conditioning allogeneic

47 hematopoietic stem cell transplantation (allo-HSCT). In order to improve their

48 outcome, we evaluated the outcome of a sequential intermediate intensity

49 conditioning regimen combining fludarabine, cytosine arabinoside, amsacrine,

50 cyclophosphamide and either total body irradiation or busulfan (FLAMSA) in

51 patients with intermediate or high risk AML in first or second complete

## FLAMSA RIC for AML in CR

52 remission (CR). A total of 265 patients (median age 55 years; range, 19-76 years)  
53 with AML who underwent allo-HSCT using a FLAMSA regimen were included. At  
54 the time of transplant, 216 (81.5%) were in CR1 and 49 (18.5%) in CR2.  
55 Cytogenetic was intermediate in 114 (43%) and poor in 42 (15.8%) patients,  
56 while 109 (41.1%) patients had a secondary AML. With a median follow-up of 46  
57 months (range, 1-145), the Kaplan-Meier estimate of overall and leukemia-free  
58 survival at 2 years were 56.1% (95%CI, 49.7-62.6) and 52.8% (95%CI, 46.4-  
59 59.2), respectively. At 2 years, the cumulative incidences of relapse and non-  
60 relapse mortality were 22.8% (95%CI, 17.6-28.4) and 24.0% (95%CI, 18.8-29.5),  
61 respectively. In multivariate analysis, patients' age and cytogenetics were the  
62 only parameters with a significant impact on overall survival. These data suggest  
63 that the FLAMSA sequential intermediate conditioning regimen provides an  
64 efficient disease control in intermediate and high-risk AML patients, including  
65 those in CR2 and with secondary AML.

66

67 Keywords: Acute myeloid leukemia; complete remission; allogeneic  
68 hematopoietic-stem-cell transplantation; sequential conditioning regimen;  
69 intermediate intensity conditioning regimen

70

FLAMSA RIC for AML in CR

71 **Introduction**

72 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective  
73 post-remission consolidation treatment, potentially curative, in acute myeloid  
74 leukemia (AML) patients[1, 2]. Reduced intensity conditioning (RIC) regimens  
75 have been developed to control or overcome toxicity and non-relapse mortality  
76 (NRM) associated with allo-HSCT[2]. RIC rely on the graft-versus-leukemia (GVL)  
77 effect mediated by the graft's immune cells[3]. RIC allo-HSCT is now widely used  
78 for AML patients with intermediate or high-risk cytogenetics, particularly in  
79 older or heavily pretreated patients and in those with medical comorbidities[2].  
80 While a significant proportion of patients are cured after RIC allo-HSCT, relapse  
81 after transplant is still the leading cause of treatment failure in the RIC setting. In  
82 patients transplanted in complete remission (CR), AML cytogenetic status and  
83 prior myelodysplastic syndrome or cytotoxic therapy are strong predictors of  
84 relapse. Therefore, the effectiveness of different intermediate intensity  
85 conditioning regimens to enhance GVL, while safely minimizing NRM has been  
86 evaluated[2, 4, 5]. One such strategy is the so-called "sequential conditioning  
87 regimen", combining a short course of intensive chemotherapy followed by a RIC  
88 allograft. Thus, the Munich group developed the FLAMSA sequential strategy  
89 combining a short course of intensive chemotherapy to improve disease control  
90 using fludarabine (Flu) 30 mg/m<sup>2</sup>/d, intermediate dose cytosine arabinoside  
91 (Ara-C) 2 g/m<sup>2</sup>/d and amsacrine (Ams) 100 mg/m<sup>2</sup>/d from day -12 to -9,  
92 followed, after a 3 days rest, by RIC using 4 Gy total body irradiation (TBI) on day  
93 -5, cyclophosphamide (Cy) 40-60 mg/Kg/d on days -4 and -3 and anti-thymocyte  
94 globulin (ATG) from days -4 to -2. This strategy has shown encouraging results in

FLAMSA RIC for AML in CR

95 relapsed or refractory AML patients'[6, 7]. In addition, Schmid et al. reported an  
96 effective disease control and a low NRM with this strategy in 23 patients with  
97 high-risk AML in CR[8]. Thereafter, 4 Gy TBI has been replaced by IV busulfan  
98 (Bu) 6.4 mg/kg total dose (or equivalent oral dose) in order to decrease the  
99 toxicity associated with TBI in elderly patients or in patients with severe  
100 comorbidities[9, 10].

101 Larger studies are needed to evaluate the role of TBI or Bu based FLAMSA  
102 sequential regimen in patients with AML in CR. We report here on 265 patients  
103 with AML in first or second CR subjected to a FLAMSA sequential allo-HSCT, TBI  
104 and Bu based FLAMSA are compared. In addition the contribution of  
105 prophylactic DLI is assessed in the subgroup of patients alive and free of disease  
106 at 6 months.

107

## 108 **Patients and methods**

### 109 *Study design and data collection*

110 This retrospective multicenter analysis was performed and approved by the  
111 Acute Leukemia Working Party (ALWP) of the EBMT group registry. The EBMT is  
112 a voluntary working group of more than 500 transplant centers; all centers are  
113 required to report annually all stem cell transplantations and follow-up. Use of  
114 patients' personal information for research purposes is authorized through the  
115 signature of an informed consent by the patients. This study included all adult  
116 patients (age >18 years) with AML in first or second morphological CR, who  
117 underwent a bone marrow (BM) or G-CSF-mobilized peripheral blood stem cells  
118 (PBSC) allo-HSCT, from an HLA matched-related (MRD) or unrelated (UD) donor  
119 between 2002 and 2014. In addition, to be eligible patients must have available

FLAMSA RIC for AML in CR

120 cytogenetics data, or secondary AML and receive a so-called “sequential”  
121 conditioning regimen. The latter was defined by the use of a short intensive  
122 course of chemotherapy combining Flu, intermediate dose Ara-C and Ams,  
123 followed after a 3 days rest by a RIC regimen combining Cy and either TBI 4 Gr or  
124 IV Bu 6.4 mg/kg total dose (or equivalent oral dose of Bu). Cytogenetic was  
125 classified according to the European Leukemia Net[11]. All allogeneic grafts were  
126 obtained from HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ-matched donors. A  
127 single HLA mismatch of 10 was allowed at the antigen or allele level. A list of the  
128 participating centers is available online (supplemental file).

129 *Statistical analysis*

130 Endpoints included overall survival (OS), leukemia-free survival (LFS),  
131 cumulative incidence of relapse (CIR), NRM, acute and chronic graft-versus-host  
132 disease (GVHD). All outcomes were measured from the time of allo-HSCT. OS was  
133 based on death, regardless of the cause. LFS was defined as survival with no  
134 evidence of relapse. NRM was defined as death in CR. Patients alive without  
135 relapse were censored at the time of last contact.

136 OS and LFS rates were calculated by the Kaplan-Meier estimator. Cumulative  
137 incidence functions were used to estimate the probabilities of acute and chronic  
138 GVHD, NRM, and relapse to accommodate competing risks. NRM and relapse  
139 were the competing risks. For acute and chronic GVHD, the competing risk was  
140 death without the event. For all prognostic analyses, patients’ median age and  
141 median year of transplant were used as a cut-off point.

142 Univariate analyses were performed using the log-rank test for OS and LFS, and  
143 Gray’s test for cumulative incidences. Chronic GVHD was analyzed as a time-  
144 dependent variable. For multivariate regression a Cox proportional hazards

FLAMSA RIC for AML in CR

145 model was build. Results were expressed as hazard ratio (HR) with 95%  
146 confidence interval (CI). All tests were two-sided and the type-1 error rate was  
147 fixed at 0.05. A landmark analysis was conducted 6 months after allo-HSCT on  
148 patients alive and free of disease to evaluate the impact of preemptive donor  
149 lymphocyte infusion (DLI) within the first 6 months on outcome. Patients  
150 developing grade II-IV aGVHD or cGVHD before DLI (group DLI) or within the  
151 first 6 months (group no DLI) were excluded from the landmark analysis.  
152 Statistical analyses were performed with SPSS 19 (SPSS Inc./IBM, Armonk, NY)  
153 and R 3.0.1 (R Development Core Team, Vienna, Austria) software packages.

154

155

FLAMSA RIC for AML in CR

156 **Results**

157 *Patient and donor characteristics*

158 A total of 265 patients were included in this study. Patients' and donors'  
159 characteristics are summarized in **Table 1**. The median age of recipients was 55  
160 (range, 19-76) years. At transplantation, 216 patients (81.5%) were in CR1 and  
161 49 (18.5%) in CR2. The median time between AML diagnosis and transplantation  
162 was 135 (43-225) days in patients with AML in CR1 and 627 (135-1701) in CR2.  
163 One hundred and nine patients (41.1%) had a secondary AML and 156 (58.9%)  
164 had a *de novo* AML including 114 (43.0%) with intermediate risk and 42 (15.8%)  
165 with high-risk cytogenetics. Of note, no patients had low risk cytogenetic among  
166 *de novo* AML. Seventy-four donors (27.9%) were MRD and 191 (72.1%) were UD.  
167 The stem cell source was BM in 14 cases (5.3%) and G-CSF-mobilized PBSCs in  
168 the remaining 251 (94.7%). All patients except for seven have received *in vivo* T  
169 cell depletion using ATG. ATG was Thymoglobulin in 102 patients (median total  
170 dose, 6 mg/kg; inter-quartile range [IQR], 5-7) and ATG Fresenius in 129  
171 patients (median total dose 60 mg/kg; IQR, 30-60); ATG administered was  
172 unknown in 24 patients.  
173 One hundred and fifty-nine patients (60%) were treated with a TBI based (TBI  
174 group) and 106 (40%) with a modified Bu based FLAMSA regimen (Bu group, 96  
175 IV Bu and 10 oral Bu). The comparison between the TBI and Bu groups is shown  
176 on **table 1**. Compared to the TBI group, patients in the Bu group were  
177 significantly older [61 years (range, 25-74) *versus* 52 years (range, 19-76);  
178  $p < 0.0001$ ], were transplanted more recently [2011 (2005-2014), *versus* 2009  
179 (2002-2014);  $p < 0.0001$ ] and included more secondary AML [59.4% *versus*  
180 28.9%;  $p < 0.0001$ ]. The median follow-up among surviving patients was 46

## FLAMSA RIC for AML in CR

181 (range, 1-145) months, being significantly longer in the TBI group, 50 (range, 1-  
182 145) months, compared to that in the Bu group, 27 (range, 3-106) months  
183 (p=0.006).

184 *Engraftment and GVHD*

185 Engraftment was successful in 153 patients (96.2%) in the TBI and 101 (95.3%)  
186 in the Bu group, respectively (p=0.56). The median time to neutrophil recovery  
187 was significantly longer in the TBI group: 17 (range, 10-74) days compared with  
188 14 (range, 8-112) in the Bu group (p<0.0001). The day-30 cumulative incidence  
189 of absolute neutrophil count > 0.5 × 10<sup>9</sup>/L was 93.9% (95% confidence interval  
190 [CI], 90.1-96.2).

191 The day-100 cumulative incidence of grade II-IV aGVHD was 28.5% (95% CI,  
192 23.1-34.1), being 30.3% (95% CI, 23.2-37.7) in the TBI group and 25.7% (95%  
193 CI, 17.6-34.6) in the Bu group (p=0.45). At 2 years, the cumulative incidence of  
194 cGVHD was 31.8% (95% CI, 25.9-37.9), being 33.5% (95%CI, 25.7-41.3) in the  
195 TBI group versus 29.1% (95% CI, 20-38.8) in the Bu group (p=0.79).

196 *Outcome*

197 Univariate and multivariate analyses of transplantation-related events are  
198 summarized in **Tables 2 and 3**, respectively. At 2 years, the cumulative  
199 incidence of NRM was 24.0% (95% CI, 18.8-29.5) (**Figure 1A**), being 19.4%  
200 (95% CI, 13.5-26.2) in the TBI and 31.1% (95% CI, 24.0-38.4) in the Bu groups  
201 (p=0.02). In multivariate analysis, there was no significant difference in NRM  
202 between the TBI and the Bu group (HR, 1.11; 95%CI, 0.62-2.01; p=0.72). NRM  
203 was related mainly to infection (n=31) and GVHD (n=19), others causes being  
204 hemorrhage (n=5), sinusoidal obstruction syndrome (SOS, n=2), cardiac toxicity  
205 (n=2), secondary malignancy (n=1), others (n=9), unknown (n=9). At 2 years, the

## FLAMSA RIC for AML in CR

206 cumulative incidence of relapse was 22.8% (95% CI, 17.6-28.4) (**Figure 1B**),  
207 with 21.2% (95% CI, 15.7-26.8) in the TBI and 25.7% (95% CI, 20.8-30.6) in the  
208 Bu group (p=0.77). In multivariate analysis, there was no significant difference in  
209 relapse incidence between the two groups (HR, 1.27; 95%CI, 0.68-2.37; p=0.4).  
210 The only parameter with a significant impact on relapse incidence in  
211 multivariate analysis was cytogenetic status: relapse was significantly increased  
212 in patients with poor as compared to intermediate cytogenetics (HR, 1.96;  
213 95%CI, 1.03-3.72; p=0.04).  
214 The Kaplan-Meier estimate of OS at 2 years was 56.1% (95% CI, 49.7-62.6)  
215 (**Figure 1C**), being 62.0% (95% CI, 54.0-70.0) in the TBI and 46.7% (95%CI,  
216 36.1-57.3) in the Bu group (p=0.14). In multivariate analysis, there was no  
217 significant difference in OS between the TBI group and the Bu group (HR, 1.09;  
218 95%CI, 0.70-1.69; p=0.70). The only parameters with a significant impact on OS  
219 in multivariate analysis were cytogenetic status and patients' age. OS was  
220 significantly lower in patients with poor as compared to intermediate  
221 cytogenetics (HR, 1.26; 95%CI, 1.06-2.92; p=0.03) and in older patients (HR,  
222 1.21; 95%CI, 1.01-1.45; p=0.04). The Kaplan-Meier estimate of LFS at 2 years  
223 was 52.8% (95% CI, 46.4-59.2) (**Figure 1D**): 58.8% (95% CI, 50.7-66.8) in the  
224 TBI and 43.2% (95%CI, 32.8-53.7) in the Bu group (p=0.14). In multivariate  
225 analysis, there was no significant difference in LFS between the TBI group and  
226 the Bu group (HR, 1.16; 95%CI, 0.76-1.78; p=0.48). No parameter had a  
227 significant impact on LFS in multivariate analysis.

228 *Prophylactic DLI*

229 Ninety-six patients alive and disease free at 6 months and without a history of  
230 grade II-IV aGVHD or cGVHD before DLI were eligible for the landmark analysis.

## FLAMSA RIC for AML in CR

231 Of these, 21 received preemptive DLI within the first 6 months, based on  
232 physician decision, while 75 did not. The outcome was significantly improved in  
233 the former group of patients. The 2-year LFS was 95% (95% CI, 86-100) in the  
234 DLI group versus 76% (95% CI, 67-86) in the no DLI group ( $p=0.03$ ), and the 2-  
235 year OS was 100% (95% CI, 100-100) in the DLI group versus 81% (95% CI, 72-  
236 91) in the no DLI group ( $p=0.10$ ). The cumulative incidence of NRM and relapse  
237 were 0% and 5% (95% CI, 0-20), respectively, in the DLI group, versus 4% (95%  
238 CI, 1-11) and 19% (95% CI, 11-29), respectively, in the no DLI group, ( $p= 0.18$   
239 and 0.11 respectively). The 2-year cumulative incidence of cGVHD was  
240 significantly higher in the DLI group, 26% (95% CI, 9-46) versus 15% (95% CI, 8-  
241 24) in the no DLI group ( $p=0.48$ ).

242

243 **Discussion**

244 Intermediate intensity conditioning regimens have been developed to decrease  
245 disease recurrence while minimizing NRM after RIC regimen. This retrospective  
246 study is the largest so far evaluating the so-called FLAMSA sequential  
247 intermediate intensity conditioning regimen in AML in CR.

248 The risk of relapse was notably high in our patients: 57% had an unfavorable  
249 karyotype or a secondary AML, and 18.5% were in CR2. Notably, the cumulative  
250 incidences of relapse and LFS were 22.8% and 52.8%, respectively. These results  
251 compare favorably with previous studies evaluating RIC regimens for AML, with  
252 relapse incidences up to 41% and LFS below 50%[12-17], but moreover with the  
253 results of myeloablative conditioning regimens, with relapse incidences ranging  
254 from 24% to 29%[12, 16]. Our results are also comparable to those of other  
255 intermediate conditioning regimens, combining Flu, ATG and 3 days of Bu[4],

## FLAMSA RIC for AML in CR

256 associated with a cumulative incidence of relapse of 29.1% and a LFS of 57%[5].  
257 Overall, this regimen is associated with a good disease control in intermediate  
258 and high risk AML, as compared to that achieved in previous studies.  
259 In patients with a median age of 55 years, and aged up to 76 years, we reported a  
260 2-year cumulative incidence of NRM of 24%. This may seem high for a RIC  
261 regimen, Russel et al. reported a reduced NRM of 6% after RIC compared to 22%  
262 after MAC in non-favorable AML in first CR[16], however, RIC regimen was non-  
263 myeloablative with low-dose TBI in most patients, leading to a cumulative  
264 incidence of relapse of 36% after RIC transplant, compare to only 22.8% in our  
265 study. Scott et al. recently reported the preliminary results of the BMT CTN 0901  
266 randomized protocol comparing MAC versus RIC in AML and myelodysplastic  
267 syndrome in CR[18]. NRM was significantly lower after RIC allo-SCT: 4.4%,  
268 versus 15.8% after MAC, while corresponding relapse rate were 48.3% versus  
269 13.5%. NRM rate are lower in this study, including in the MAC group, consisting  
270 of a majority of reduced toxicity regimen combining Flu and Bu. However, this  
271 study includes only selected patients up to 65 years, while in our cohort patients  
272 up to 76 years were treated. Therefore our NRM is comparable to the NRM  
273 reported in some of the largest studies on RIC regimen for AML[12, 13].  
274 Regarding conventional MAC regimen, similar rate of NRM have been reported in  
275 prospective studies: 22% in the study by Russel et al. [16] and 25/7% in the  
276 study by Lee et al.[19]. However, in these prospective studies, patients were  
277 selected and younger with a median age of 42 and 41 years old respectively,  
278 compare to a median age of 55 years in our study. Therefore our NRM rate  
279 compare favorably with traditional myeloablative regimen. Previous report  
280 evaluating FLAMSA sequential regimen reported a 2-year NRM of 22% both in

FLAMSA RIC for AML in CR

281 relapse/refractory AML[7] and in AML in CR[8]. Of note, we reported only 2  
282 deaths related to cardiac toxicity, a known side effect of amsacrine[20] and there  
283 was no increase in the mortality related to sinusoidal obstruction syndrome,  
284 with only 2 deaths reported.

285 Taken together, the low cumulative incidence of relapse and the NRM led to an  
286 OS of 56.1% at 2 years, which compare favorably with result of the previously  
287 cited studies evaluating both RIC (OS range from 36% to 55%)[12-16] and  
288 myeloablative regimens (OS range from 57% to 53%)[12, 16].

289 The patients' outcome was similar using either the TBI or the Bu based FLAMSA  
290 regimen. Although NRM was higher in patients receiving Bu in univariate  
291 analysis, after adjustment for patient age, among others, there was no difference  
292 in NRM between the two conditioning regimens in multivariate analysis. Given  
293 TBI is a the major risk factor of long-term complications [21] and the favorable  
294 safety profile associated with the use of IV Bu[22], IV Bu appears as an effective  
295 alternative to TBI in the FLAMSA sequential approach.

296 Attention must be paid to elderly patients when using FLAMSA sequential  
297 regimen. While McClure et al. reported no impact of patients' age on the outcome  
298 after RIC regimen allo-SCT[23], older age at transplant was associated with a  
299 significantly lower OS in our multivariate analysis. This difference seems to be  
300 related to an increased NRM in elderly patients; however, given the retrospective  
301 nature of this analysis, we were not able to identify the exact nature of those  
302 deaths. Ultimately, careful screening of co-morbidities must be performed in  
303 elderly patients before using intermediate intensity conditioning such as the  
304 FLAMSA sequential regimen.

305 In multivariate analysis, poor risk cytogenetic status was associated with a

FLAMSA RIC for AML in CR

306 significant increase in relapse and a decrease in OS. Therefore, despite the  
307 increased cytotoxicity, the FLAMSA sequential regimen does not overcome the  
308 bad prognosis of poor-risk cytogenetic. Development of a new strategy to  
309 decrease relapse risk in those patients remains indispensable. In our study, some  
310 patients received prophylactic DLI based on physician decision and, while we  
311 recognize that given the retrospective nature of our study, exact reason guiding  
312 decision to give prophylactic DLI is unknown, use of prophylactic DLI seems to  
313 be a valuable option to decrease relapse risk. Indeed, in a landmark analysis of  
314 patients alive and disease-free at 6 months, the LFS was significantly improved  
315 in patients who received prophylactic DLI, compared to those who did not.  
316 Furthermore, other strategies, such as early administration of the  
317 hypomethylating agent azacytidine or of FLT3-specific tyrosine kinase inhibitor  
318 seem promising[24, 25].  
319 Given his retrospective nature, our study does have several obvious biases.  
320 Molecular marker and minimal residual disease before transplant were not  
321 available for all patients, precluding the evaluation of their prognostic value. As it  
322 was not a prospective study, the choice of the allocation to the FLAMSA regimen  
323 was based on physicians' preferences and we cannot exclude a bias in patients'  
324 selection. However, the homogeneity of the data in term of disease and  
325 transplant characteristics' strengthen our study and make the conclusion more  
326 robust.  
327 Overall, our results suggest that the sequential FLAMSA conditioning regimen  
328 using either TBI or Bu may be a valid approach for intermediate or high risk AML  
329 transplanted in CR. This regimen is associated with a low incidence of relapse,  
330 although disease progression is still expected in patients with high-risk

FLAMSA RIC for AML in CR

331 cytogenetic. However, advanced age patients have an increased risk of NRM and  
332 particular attention should be paid to comorbidities, supportive care and dose of  
333 TBI or Bu used in this patients. Our result pave the way for future studies that  
334 should compare such sequential approaches with standard approached and  
335 include minimal residual monitoring to decipher the exact impact of the  
336 chemotherapy include in our sequential regimen before the RIC allo-SCT. Overall,  
337 our study provides a framework for further refinement of intermediate intensity  
338 conditioning designed to improve disease control without increasing toxicity in  
339 AML in CR.

#### 340 **Acknowledgements:**

341 The study was supported by a grant from the “Association for Training,  
342 Education and Research in Hematology, Immunology and Transplantation”  
343 (ATERHIT, Nantes, France).

#### 344 **Authors' contributions**

345 F.M., M.L., B.N.S., M.Mohty and A.N. designed the research and/or analyzed data;  
346 G.S., J.B, A.G., J.T., M.Michallet, N.K., C.S., A.H., M.H. and M.Mohty provided  
347 important clinical data; F.M. wrote the first draft of the manuscript; and all  
348 authors approved the final version of the manuscript.

#### 349 **Competing interests**

350 The authors declare that they have no competing interests in relation with the  
351 content of this analysis.

#### 352 **Funding**

353 Not applicable.

354

355 **References**

- 356 [1] Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. *N Engl J*  
357 *Med.* 2015;373:1136-1152.
- 358 [2] Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M. Reduced  
359 intensity conditioning allogeneic hematopoietic cell transplantation for adult  
360 acute myeloid leukemia in complete remission - a review from the Acute  
361 Leukemia Working Party of the EBMT. *Haematologica.* 2015;100:859-869.
- 362 [3] Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions  
363 after bone marrow transplantation. *Blood.* 1990;75:555-562.
- 364 [4] Mohty M, Malard F, Blaise D, et al. Reduced-toxicity conditioning with  
365 fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior  
366 to allogeneic stem cell transplantation: results of a multicenter prospective  
367 phase 2 trial. *Cancer.* 2015;121:562-569.
- 368 [5] Oudin C, Chevallier P, Furst S, et al. Reduced-toxicity conditioning prior to  
369 allogeneic stem cell transplantation improves outcome in patients with myeloid  
370 malignancies. *Haematologica.* 2014;99:1762-1768.
- 371 [6] Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen  
372 of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell  
373 transplantation, and prophylactic donor lymphocyte transfusion in high-risk  
374 acute myeloid leukemia and myelodysplastic syndrome. *J Clin Oncol.*  
375 2005;23:5675-5687.
- 376 [7] Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in  
377 refractory acute myeloid leukemia after sequential treatment with  
378 chemotherapy and reduced-intensity conditioning for allogeneic stem cell  
379 transplantation. *Blood.* 2006;108:1092-1099.
- 380 [8] Schmid C, Schleuning M, Hentrich M, et al. High antileukemic efficacy of an  
381 intermediate intensity conditioning regimen for allogeneic stem cell  
382 transplantation in patients with high-risk acute myeloid leukemia in first  
383 complete remission. *Bone Marrow Transplant.* 2008;41:721-727.
- 384 [9] Kröger N, Zabelina T, Wolschke C, et al. Induction Chemotherapy Followed  
385 Immediately by Busulfan-Based Reduced Conditioning and Allografting in  
386 Elderly Patients with Advanced MDS or sAML. *Blood.* 2015;114:3387-3387.
- 387 [10] Christopheit M, Badbaran A, Alawi M, et al. Correlation of somatic mutations  
388 with outcome after FLAMSA-busulfan sequential conditioning and allogeneic  
389 stem cell transplantation in patients with MDS. *Eur J Haematol.* 2015.
- 390 [11] Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute  
391 myeloid leukemia in adults: recommendations from an international expert  
392 panel, on behalf of the European LeukemiaNet. *Blood.* 2010;115:453-474.
- 393 [12] Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced  
394 intensity and myeloablative conditioning regimen in HLA identical sibling  
395 allogeneic haematopoietic stem cell transplantation for patients older than 50  
396 years of age with acute myeloblastic leukaemia: a retrospective survey from the  
397 Acute Leukemia Working Party (ALWP) of the European group for Blood and  
398 Marrow Transplantation (EBMT). *Leukemia.* 2005;19:2304-2312.
- 399 [13] Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk  
400 acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity  
401 conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host  
402 disease is the strongest factor improving survival. *J Clin Oncol.* 2008;26:577-584.

## FLAMSA RIC for AML in CR

- 403 [14] Warlick ED, Paulson K, Brazauskas R, et al. Effect of postremission therapy  
404 before reduced-intensity conditioning allogeneic transplantation for acute  
405 myeloid leukemia in first complete remission. *Biol Blood Marrow Transplant.*  
406 2014;20:202-208.
- 407 [15] Yeshurun M, Labopin M, Blaise D, et al. Impact of postremission  
408 consolidation chemotherapy on outcome after reduced-intensity conditioning  
409 allogeneic stem cell transplantation for patients with acute myeloid leukemia in  
410 first complete remission: a report from the Acute Leukemia Working Party of the  
411 European Group for Blood and Marrow Transplantation. *Cancer.* 2014;120:855-  
412 863.
- 413 [16] Russell NH, Kjeldsen L, Craddock C, et al. A comparative assessment of the  
414 curative potential of reduced intensity allografts in acute myeloid leukaemia.  
415 *Leukemia.* 2015;29:1478-1484.
- 416 [17] Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of  
417 adults with relapsed AML after reduced intensity conditioning for allogeneic  
418 stem cell transplantation. *Blood.* 2012;119:1599-1606.
- 419 [18] Scott BL, Pasquini MC, Logan B, et al. Results of a Phase III Randomized,  
420 Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus  
421 Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome  
422 (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Cl...  
423 *Blood.* 2015;126:LBA-8-LBA-8.
- 424 [19] Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning  
425 regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. *J*  
426 *Clin Oncol.* 2013;31:701-709.
- 427 [20] Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence,  
428 treatment and prevention. *Drug safety.* 2000;22:263-302.
- 429 [21] Mohty M, Malard F, Savani BN. High-Dose Total Body Irradiation and  
430 Myeloablative Conditioning before Allogeneic Hematopoietic Cell  
431 Transplantation: Time to Rethink? *Biol Blood Marrow Transplant.* 2015;21:620-  
432 624.
- 433 [22] Russell JA, Kangaroo SB. Therapeutic drug monitoring of busulfan in  
434 transplantation. *Curr Pharm Des.* 2008;14:1936-1949.
- 435 [23] McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of  
436 reduced-intensity hematopoietic cell transplantation for older patients with  
437 acute myeloid leukemia in first complete remission or with myelodysplastic  
438 syndrome. *J Clin Oncol.* 2010;28:1878-1887.
- 439 [24] Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of  
440 regulatory T cells after allogeneic stem cell transplantation in patients with acute  
441 myeloid leukemia (AML). *Blood.* 2012;119:3361-3369.
- 442 [25] Schiller GJ, Tuttle P, Desai P. Allogeneic Hematopoietic Stem Cell  
443 Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role  
444 for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. *Biol Blood Marrow*  
445 *Transplant.* 2016;22:982-990.
- 446
- 447

FLAMSA RIC for AML in CR

448 **Figure legend:**

449 **Figure 1.** Outcome after allo-HSCT. Cumulative incidence of non-relapse

450 mortality (A); cumulative incidence of relapse (B); overall survival (C); and

451 leukemia-free survival (D). NRM indicates non-relapse mortality.

452

Accepted Manuscript

## FLAMSA RIC for AML in CR

453 **Table 1.** Study population and transplant characteristics  
 454

Characteristic (%)	Total (n = 265)	FLAMSA TBI 4 Gy (n=159)	FLAMSA Bu (n=106)	P
Patient age, median (range)	55 (19-76)	52 (19-76)	61 (25-74)	<0.0001
Patients < 55 years	132 (49.6%)	104 (65.4%)	28 (26.4%)	
Patients ≥ 55 years	133 (50.4%)	55 (34.6%)	78 (73.6%)	
Year of transplant, median (range)	2010 (2002-2014)	2009 (2002-2014)	2011 (2005-2014)	<0.0001
Patient gender (female)	122 (46.2%)	82 (51.9%)	40 (37.7%)	0.02
Donor gender (female)	80 (30.5%)	52 (33.3%)	28 (26.4%)	0.23
Female donor to male patient	26 (10.0%)	16 (10.3%)	10 (9.4%)	0.81
Karnofsky performance status				
≥90%	179 (70%)	107 (71%)	72 (70%)	
80%	65 (26%)	39 (26%)	26 (25%)	0.82
≤70%	10 (4%)	5 (3%)	5 (5%)	
Unknown	11	8	3	
Donor CMV negative to patient CMV positive	51 (19.6%)	34 (21.8%)	17 (16.0%)	0.41
Disease status				
CR1	216 (81.5%)	127 (79.9%)	89 (84.0%)	0.40
CR2	49 (18.5%)	32 (20.1%)	17 (16.0%)	
Median time from diagnosis to transplant				
CR1 patients, days (range)	135 (43-225)	130 (43-948)	154 (43-827)	0.02
CR2 patients, days (range)	627 (135-1701)	631 (135-1508)	547 (166-1701)	0.36
Cytogenetic risk				
Intermediate	114 (43.0%)	82 (51.6%)	32 (30.2%)	
Poor	42 (15.8%)	31 (19.5%)	11 (10.4%)	<0.0001
Secondary AML	109 (41.1%)	46 (28.9%)	63 (59.4%)	
Donor type				
Matched related donor	74 (27.9%)	50 (31.4%)	24 (22.6%)	0.12
Unrelated donor*	191 (72.1%)	109 (68.6%)	82 (77.4%)	
Stem cell source				
BM	14 (5.3%)	10 (6.3%)	4 (3.8%)	0.37
PBSC	251 (94.7%)	149 (93.7%)	102 (96.2%)	
<i>In vivo</i> T-cell depletion				
No	7 (2.6%)	5 (3.1%)	2 (1.9%)	0.53
Yes	258 (97.4%)	154 (96.9%)	104 (98.1%)	
GVHD prophylaxis				
CsA + MMF	216 (81.8%)	129 (81.6%)	87 (82.1%)	0.93
Others	48 (18.2%)	29 (18.4%)	19 (17.9%)	

455 Abbreviations : CMV indicates cytomegalovirus; CR1. first complete remission; CR2. second  
 456 complete remission; AML. acute myeloid leukemia; BM. bone marrow; PBSC. peripheral blood stem  
 457 cells; TNC. total nucleated cells; Bu. busulfan; TBI. total body irradiation; GVHD. graft-versus-host  
 458 disease; CsA. Cyclosporine A; MMF. mycophenolate mofetil.  
 459 \* 49 patients (%) received a mismatched unrelated donor, being 27 in the TBI group and 22 in the  
 460 Bu group.

## FLAMSA RIC for AML in CR

461 **Table 2.** Transplant-related events: univariate analysis  
462

	NRM	RI	OS	LFS
Conditioning				
TBI group	19.4% (13.5-26.2)	21.2 % (15-28.2)	62 % (54-70)	58.8 % (50.7-66.8)
Bu group	31.1% (24-38.4)	25.7 % (17-35.2)	46.7 % (36.1-57.3)	43.2 % (32.8-53.7)
P value	<b>0.02</b>	0.77	0.14	0.14
Patient age				
< 55 years	17.8% (11.5-25.3)	23.9 % (16.4-32.1)	62.2 % (53.2-71.2)	57.9 % (48.8-67.1)
≥ 55 years	29.7% (21.8-38)	21.8 % (14.9-29.5)	50.6 % (41.6-59.7)	48.1 % (39.2-57)
P value	<b>0.008</b>	0.90	<b>0.005</b>	<b>0.02</b>
Status at transplant				
CR1	23.2% (17.6-29.4)	23 % (17.3-29.3)	57.5 % (50.4-64.6)	53.2 % (46.1-60.4)
CR2	27.1% (21.1-33.5)	22 % (11.2-35.2)	50.6 % (36.1-65.2)	50.8 % (36.3-65.3)
P value	0.68	0.70	0.98	0.99
Patient gender				
Male	28.2 % (20.8-36.1)	23.8 % (16.8-31.4)	49.4 % (40.7-58.1)	47.6 % (38.9-56.2)
Female	18 % (12-25.1)	21.7 % (14.4-30.1)	65.4 % (56.2-74.5)	59.8 % (50.3-69.3)
P value	0.052	0.54	<b>0.049</b>	0.10
Donor gender				
Male	22.9 % (16.9-29.5)	23.7 % (17.5-30.5)	55.1 % (47.4-62.8)	53.4 % (45.7-61.1)
Female	27.5 % (21-34.3)	21.6 % (12.7-32)	56.6 % (44.7-68.4)	49.4 % (37.5-61.4)
P value	0.22	0.58	0.39	0.48
Female to male				
Yes	23.6% (18.1-29.5)	23 % (17.5-29)	56 % (49.1-62.8)	53.2 % (46.3-60)
No	27.7% (21.9-33.7)	24 % (9.4-42.2)	54.5 % (34.6-74.4)	46.2 % (26.3-66.1)
P value	0.32	0.95	0.28	0.34
Donor				
MRD	13.8% (7-22.8)	30.6 % (20.3-41.5)	62.5 % (51-73.9)	54.4 % (42.7-66.1)
UD	28.4% (18.5-39.1)	19.5 % (13.8-26)	53.5 % (45.8-61.2)	52.1 % (44.4-59.8)
P value	<b>0.04</b>	<b>0.047</b>	0.54	0.94
Year				
< 2010	13.9% (8.3-20.9)	23.5 % (16.2-31.6)	66.3 % (57.6-75)	61.9 % (53-70.9)
≥ 2010	33.3% (25-41.8)	23.3 % (16-31.6)	46.3 % (37.1-55.5)	43.4 % (34.2-52.5)
P value	<b>0.0008</b>	0.61	<b>0.003</b>	<b>0.02</b>
Cytogenetics				
Intermediate	20.6 % (12.6-30)	21.7 % (14.5-29.8)	61.2 % (52-70.4)	56.9 % (47.5-66.2)
Poor	19.6 % (11.8-28.9)	35.2 % (20.6-50.2)	47.3 % (31.6-62.9)	45.2 % (29.6-60.7)
Secondary AML	30.3 % (20.9-40.3)	19.1 % (11.4-28.3)	53.7 % (42.9-64.5)	50.6 % (39.8-61.4)
P value	0.10	0.08	0.46	0.69

463 Abbreviations : NRM indicates non-relapse mortality; RI, relapse incidence; OS, overall survival;

464 LFS, leukemia-free survival; TBI, total body irradiation; Bu, busulfan; CR1, first complete

465 remission; CR2, second complete remission; MRD, matched related donor; UD, unrelated donor;

466 CMV, cytomegalovirus; AML acute myeloid leukemia.

467 Bold denotes statistically significant.

468

469

## FLAMSA RIC for AML in CR

470 **Table 3.** Transplant-related events: multivariate analysis  
 471

Outcome	Hazard ratio (95% confidence interval)	P value
Non-relapse mortality		
Busulfan versus TBI based conditioning	1.11 (0.62-2.01)	0.72
Age at transplant (per 10 years)	1.18 (0.93-1.50)	0.18
Status at transplant (CR2 versus CR1)	1.31 (0.69-2.50)	0.41
Unrelated donor versus MRD	1.77 (0.92-3.39)	0.09
Cytogenetic		
Poor versus intermediate	1.07 (0.47-2.41)	0.87
Secondary AML versus intermediate	1.32 (0.73-2.39)	0.35
Patient gender (female versus male)	0.68 (0.39-1.19)	0.18
Female donor to male patient versus others	1.45 (0.65-3.26)	0.37
Year of transplant	1.11 (0.99-1.24)	0.07
Relapse incidence		
Busulfan versus TBI based conditioning	1.27 (0.68-2.37)	0.44
Age at transplant (per 10 years)	1.23 (0.96-1.58)	0.11
Status at transplant (CR2 versus CR1)	1.24 (0.62-2.48)	0.54
Unrelated donor versus MRD	0.62 (0.36-1.07)	0.08
Cytogenetic		
Poor versus intermediate	<b>1.96 (1.03-3.72)</b>	<b>0.04</b>
Secondary AML versus intermediate	0.89 (0.48-1.68)	0.73
Patient gender (female versus male)	0.82 (0.48-1.41)	0.48
Female donor to male patient	0.81 (0.34-1.95)	0.64
Year of transplant	0.98 (0.87-1.09)	0.69
Overall survival		
Busulfan versus TBI based conditioning	1.09 (0.70-1.69)	0.70
Age at transplant (per 10 years)	<b>1.21(1.01-1.45)</b>	<b>0.04</b>
Status at transplant (CR2 versus CR1)	1.35 (0.83-2.19)	0.23
Unrelated donor versus MRD	1.11 (0.73-1.69)	0.63
Cytogenetic		
Poor versus intermediate	<b>1.76 (1.06-2.92)</b>	<b>0.03</b>
Secondary AML versus intermediate	1.17 (0.75-1.84)	0.49
Patient gender (female versus male)	0.71 (0.48-1.07)	0.10
Female donor to male patient versus others	1.15 (0.63-2.10)	0.65
Year of transplant	1.08 (0.99-1.18)	0.07
Leukemia-free survival		
Busulfan versus TBI based conditioning	1.16 (0.76-1.78)	0.48
Age at transplant (per 10 years)	1.19 (1.00-1.41)	0.05
Status at transplant (CR2 versus CR1)	1.23 (0.77-1.98)	0.39
Unrelated donor versus MRD	0.98 (0.66-1.47)	0.94
Cytogenetic		
Poor versus intermediate	1.50 (0.92-2.47)	0.11
Secondary AML versus intermediate	1.09 (0.71-1.68)	0.68
Patient gender (female versus male)	0.76 (0.52-1.11)	0.16
Female donor to male patient versus others	1.10 (0.61-1.99)	0.76
Year of transplant	1.04 (0.97-1.13)	0.28

472 Abbreviations: Bu indicates busulfan; CR2, second complete remission; CR1, first complete  
 473 remission; MRD, matched related donor; AML, acute myeloid leukemia.  
 474 Bold denotes statistically significant.

475  
 476